PYC THERAPEUTICS LIMITED - News & Media

0.42%

$1.19

Market Cap $691.1M

Healthcare Biotechnology

PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company... PYC Therapeutics Limited is an Australia-based clinical-stage biotechnology company creating a new generation of ribonucleic acid (RNA) therapies to change the lives of patients with genetic diseases. The Company utilizes its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing and commercially proven RNA therapeutic class. Its drug development programs target monogenic diseases - the indications with the highest likelihood of success in clinical development. Its first-in-class drug programs include Retinitis Pigmentosa type 11, (VP-001), Polycystic Kidney Disease, (PYC-003), Autosomal Dominant Optic Atrophy (ADOA) (PYC-001) and Phelan-McDermid Syndrome (PMS) (PYC-002). The Company's VP-001 program is a lead asset for a blinding eye disease of childhood progressed through multiple patient cohorts in the ongoing single ascending dose clinical trial. ADOA is a progressive and blinding eye disease.More

BPH Energy (ASX:BPH) heads to Federal Court to fight PEP-11 decision.

Articles & Videos

PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit

PYC Therapeutics (ASX:PYC) has jumped on Friday as it moves on the the next stage of its escalating single-dose study using its drug PYC-001 to treat a genetic children’s disease causing blindness.(Most gains, however, were quickly sold off.)Autosomal Dominant Optic Atrophy (ADOA)...

31 Jan 2025 10:47 (AEDT)

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last $1.19		Change 0.005(0.42%)		Mkt cap ! $691.1M

Open	High	Low	Value	Volume
$1.20	$1.21	$1.19	$410.5K	343.0K

Buyers (Bids)

No.	Vol.	Price($)
1	15611	$1.19

Sellers (Offers)

Price($)	Vol.	No.
$1.20	20000	1

View Market Depth

No.	Vol.	Price($)
1	15611	1.185
2	8874	1.180
4	77891	1.150
1	50000	1.140
1	889	1.125

Price($)	Vol.	No.
1.200	20000	1
1.205	2270	1
1.220	3582	2
1.240	15563	2
1.250	4333	2

Last trade - 16.10pm 13/06/2025 (20 minute delay)

PYC (ASX) Chart

PYC THERAPEUTICS LIMITED - News & Media

Articles & Videos

PYC Therapeutics jumps just shy of +4% as second-stage blindness drug study greenlit

Scientific conference spotlights PYC's work on blindness disease treatment

PYC Therapeutics moves into final stage of child blindness study

Biotech stock PYC doses first patient in rare blindness-causing disease trial

PYC achieves key designation for drug aiming to treat blinding eye disease ADOA

PYC commences new study on drug for eye condition Retinitis Pigmentosa type 11

PYC achieved protein-restoration on genetic condition PMS ahead of human trialling

PYC Therapeutics takes Polycystic Kidney Disease drug to human trials

PYC Therapeutics (ASX:PYC) doses first patient in eye disease trial

PYC Therapeutics (ASX:PYC) lands FDA clearance for first human trials of RP11 treatment drug

Buyers (Bids)

Sellers (Offers)

Top Stories